199 related articles for article (PubMed ID: 22308267)
21. Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.
Irie K; Yanagita RC
Chem Rec; 2014 Apr; 14(2):251-67. PubMed ID: 24677503
[TBL] [Abstract][Full Text] [Related]
22. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
23. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
24. Function-Oriented Synthesis: Design, Synthesis, and Evaluation of Highly Simplified Bryostatin Analogues.
Wender PA; Sloane JL; Luu-Nguyen QH; Ogawa Y; Shimizu AJ; Ryckbosch SM; Tyler JH; Hardman C
J Org Chem; 2020 Dec; 85(23):15116-15128. PubMed ID: 33200928
[TBL] [Abstract][Full Text] [Related]
25. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
26. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
27. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway.
Staveness D; Abdelnabi R; Near KE; Nakagawa Y; Neyts J; Delang L; Leyssen P; Wender PA
J Nat Prod; 2016 Apr; 79(4):680-4. PubMed ID: 26900711
[TBL] [Abstract][Full Text] [Related]
29. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
30. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Keck GE; Poudel YB; Rudra A; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4084-8. PubMed ID: 22579485
[TBL] [Abstract][Full Text] [Related]
31. Isolation, analytical measurements, and cell line studies of the iron-bryostatin-1 complex.
Plummer S; Manning T; Baker T; McGreggor T; Patel M; Wylie G; Phillips D
Bioorg Med Chem Lett; 2016 May; 26(10):2489-2497. PubMed ID: 27068183
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Abdelnabi R; Staveness D; Near KE; Wender PA; Delang L; Neyts J; Leyssen P
Biochem Pharmacol; 2016 Nov; 120():15-21. PubMed ID: 27664855
[TBL] [Abstract][Full Text] [Related]
33. Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1.
Grant S
Front Biosci; 1997 Jun; 2():d242-52. PubMed ID: 9195893
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties.
Andrews IP; Ketcham JM; Blumberg PM; Kedei N; Lewin NE; Peach ML; Krische MJ
J Am Chem Soc; 2014 Sep; 136(38):13209-16. PubMed ID: 25207655
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.
Ketcham JM; Volchkov I; Chen TY; Blumberg PM; Kedei N; Lewin NE; Krische MJ
J Am Chem Soc; 2016 Oct; 138(40):13415-13423. PubMed ID: 27676096
[TBL] [Abstract][Full Text] [Related]
36. Bryostatin 1 causes attenuation of TPA‑mediated tumor promotion in mouse skin.
Zeng N; Xu Y; Wu Y; Hongbo T; Wu M
Mol Med Rep; 2018 Jan; 17(1):1077-1082. PubMed ID: 29115558
[TBL] [Abstract][Full Text] [Related]
37. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
Stanwell C; Gescher A; Bradshaw TD; Pettit GR
Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895
[TBL] [Abstract][Full Text] [Related]
38. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
39. The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.
Kedei N; Telek A; Czap A; Lubart ES; Czifra G; Yang D; Chen J; Morrison T; Goldsmith PK; Lim L; Mannan P; Garfield SH; Kraft MB; Li W; Keck GE; Blumberg PM
Biochem Pharmacol; 2011 Jun; 81(11):1296-308. PubMed ID: 21458422
[TBL] [Abstract][Full Text] [Related]
40. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
